When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Common cutaneous drug reactions

Last reviewed: 16 Mar 2025
Last updated: 22 Nov 2024

Summary

Definition

History and exam

Key diagnostic factors

  • presence of risk factors
  • history of drug exposure
  • skin lesions
  • variable skin reactions within 5 to 15 minutes of drug exposure
  • variable skin reactions within a few hours of drug exposure
  • variable skin reactions within 2 weeks of drug exposure
  • variable skin reactions within months to years of drug exposure
  • previous exposure and reaction to drug
Full details

Other diagnostic factors

  • pruritus
  • associated non-cutaneous features
  • pain
Full details

Risk factors

  • virus infections
  • HIV infection
  • HLA-B*5701 polymorphism
  • HLA-B*1502 polymorphism
  • HLA-B*5801 polymorphism
  • female sex
Full details

Diagnostic investigations

Investigations to consider

  • blood (whole blood, plasma, serum) drug concentration
  • serum tryptase concentration (anaphylaxis)
  • complement pathway assay
  • histology of lesion biopsy
  • FBC and differential
  • anti-histone antibodies to single-stranded DNA (lupus-like syndrome)
  • skin tests (prick tests, intradermal tests, patch tests)
Full details

Emerging tests

  • drug-specific IgE
  • basophil activation test
  • lymphocyte proliferation assay (LPA/LTT)
  • enzyme-linked immunospot assay (ELISPOT test)

Treatment algorithm

ACUTE

serious cutaneous adverse reactions

non-serious cutaneous adverse reactions

ONGOING

following acute episode

Contributors

Authors

Associate Professor

Consultant Dermatologist

Faculty of Medicine

University of Southampton

Southampton

UK

Disclosures

MA-J declares that he has no competing interests.

Dr Michael Ardern-Jones would like to gratefully acknowledge Dr Wei Yann Haw, Dr Anne Holbrook, Dr Hermenio Lima, and Dr Jeffrey K. Aronson, the previous contributors to this topic.

Disclosures

WYH, AH and HL declare that they have no competing interests. JKA is editor of Meyler's Side Effects of Drugs and its annual companion volumes, the Side Effects of Drugs Annuals.

Peer reviewers

Specialist Dermatologist

Ayza Skin & Research Center

Lalamusa

Pakistan

Disclosures

SAJ declares that he has no competing interests.

Dean

College of Pharmacy, Nursing, and Health Sciences

Purdue University

West Lafayette

IN

Disclosures

CKS declares that he has no competing interests.

  • Common cutaneous drug reactions images
  • Differentials

    • Systemic lupus erythematosus
    • Auto-immune blistering disorders
    • Staphylococcal scalded skin syndrome
    More Differentials
  • Guidelines

    • Anaphylaxis: a 2023 practice parameter update
    • Drug allergy: a 2022 practice parameter
    More Guidelines
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer